VBI Vaccines has tapped John Dillman as chief commercial officer. In that role, he has been charged with leading VBI’s commercial strategy, sales and sales operations, including the commercialization of VBI’s hepatitis vaccine PreHevbrio.

Prior to formally arriving at VBI, Dillman was the company’s commercial lead at Syneos Health. VBI has had a commercialization partnership with Syneos Health since 2019.